Veeva Systems VEEV
Veeva Systems is a cloud software provider for the healthcare industry, offering CRM and data management solutions for pharmaceutical and life sciences companies. Veeva Systems shows solid financial health (8.92) with net cash (DN/EBITDA -6.59) and robust growth (8.31) of 17.6% in revenue, although its valuation is demanding (P/E 46.09). The launch of AI products for clinical trials reinforces its competitive position and growth potential.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Veeva Systems is a cloud software provider for the healthcare industry, offering CRM and data management solutions for pharmaceutical and life sciences companies. Veeva Systems shows solid financial health (8.92) with net cash (DN/EBITDA -6.59) and robust growth (8.31) of 17.6% in revenue, although its valuation is demanding (P/E 46.09). The launch of AI products for clinical trials reinforces its competitive position and growth potential.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.9 |
| Quality / Moat | 7.7 |
| Valuation | 3.6 |
| Growth | 8.6 |
| Dividend | 1.5 |
| Momentum | 4.2 |
| Risk & Context | 6.5 |
OVERALL SCORE: 6.3/10
Context and risks
The macro context (rates, oil, geopolitics) does not materially affect Veeva's healthcare software business. Its net cash balance sheet and 17.6% revenue growth insulate it from relevant macro factors.
News considered in the analysis
- Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup — Lanzamiento de un producto de IA con potencial para acelerar los ensayos clínicos, un diferenciador clave que puede impulsar la adopción y el crecimiento de ingresos.
- Veeva Systems (VEEV) Could Be 29% Undervalued Following Its New AI Study Design Launch — Análisis de valoración que sugiere un potencial alcista del 29% tras el lanzamiento del nuevo producto de IA, lo que refuerza la tesis de crecimiento.
- How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients — La expansión de la IA agéntica y la captación de nuevos clientes farmacéuticos son señales positivas para el crecimiento futuro, aunque el mercado ya lo ha descontado parcialmente.
- Veeva (VEEV) Down 2.6% Since Last Earnings Report: Can It Rebound? — Artículo sobre la evolución del precio tras los resultados, sin información nueva sobre fundamentales.
- Veeva Systems (VEEV) Outperforms Broader Market: What You Need to Know — Comentario genérico sobre el rendimiento relativo de la acción, sin información nueva.
Verdict: Hold, with a positive bias for long-term investors who trust in the execution of its AI strategy and expansion within the pharmaceutical sector.
Main risk: The main risk is the demanding valuation (P/E 46.09, EV/EBITDA 35.67) which leaves little room for error: any slowdown in growth or adoption of its new AI products could trigger a significant correction.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →